An intensive care nurse treating a newborn with RSV in Germany. Sanofi’s new antibody is designed to protect all infants from the common and occasionally severe infection. (Marijan Murat/picture-alliance/dpa/AP Images)

With new RSV an­ti­body, Sanofi looks to avoid a re­peat of a 20-year-old pric­ing con­tro­ver­sy

Twen­ty-four years ago, the FDA ap­proved a drug as con­tro­ver­sial as it was in­no­v­a­tive.

Known as Synagis, it was OK’d for pro­tect­ing cer­tain in­fants against res­pi­ra­to­ry syn­cy­tial virus, or RSV, the lead­ing cause of in­fant hos­pi­tal­iza­tion in the US and Eu­rope. It was the first an­ti­body ap­proved for an in­fec­tious dis­ease, a fore­run­ner of the an­ti­body treat­ments de­ployed dur­ing the pan­dem­ic to treat or pro­tect peo­ple from Covid-19.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.